Zocdoc vs Eli Lilly

Side-by-side comparison of AI visibility scores, market position, and capabilities

Zocdoc leads in AI visibility (86 vs 81)
Zocdoc logo

Zocdoc

GrowthHealthTech

Patient Scheduling Marketplace

Zocdoc is a patient appointment booking marketplace that lets patients find and book in-network doctors in real time, with insurance verification and same-day availability filters.

AI VisibilityBeta
Overall Score
A86
Category Rank
#11 of 596
AI Consensus
70%
Trend
stable
Per Platform
ChatGPT
88
Perplexity
80
Gemini
92

About

Zocdoc operates a two-sided marketplace connecting patients with physicians, dentists, and mental health providers who accept their specific insurance and have real-time appointment availability. Patients can filter by specialty, insurance plan, location, and next available appointment, then book online in seconds — eliminating the phone-tag and hold-time historically required to schedule care. The platform verifies insurance acceptance in real time and sends automated reminders to reduce no-shows.

Full profile
Eli Lilly logo

Eli Lilly

LeaderHealthcare

General

Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A81
Category Rank
#17 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
80
Perplexity
75
Gemini
77

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.

Full profile

AI Visibility Head-to-Head

86
Overall Score
81
#11
Category Rank
#17
70
AI Consensus
71
stable
Trend
stable
88
ChatGPT
80
80
Perplexity
75
92
Gemini
77
92
Claude
86
86
Grok
85

Key Details

Category
Patient Scheduling Marketplace
General
Tier
Growth
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Zocdoc
Patient Scheduling Marketplace

Integrations

Eli Lilly is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.